The estimated Net Worth of Matthew Norwood is at least $2.77 mil dollars as of 12 October 2016. Mr. Norwood owns over 1,000 units of Obalon Therapeutics Inc stock worth over $2,770 and over the last 8 years he sold OBLN stock worth over $0. In addition, he makes $0 as Vice President of Sales at Obalon Therapeutics Inc.
Matthew has made over 1 trades of the Obalon Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of OBLN stock worth $15,000 on 12 October 2016.
The largest trade he's ever made was buying 1,000 units of Obalon Therapeutics Inc stock on 12 October 2016 worth over $15,000. On average, Matthew trades about 333 units every 0 days since 2016. As of 12 October 2016 he still owns at least 1,000 units of Obalon Therapeutics Inc stock.
You can see the complete history of Mr. Norwood stock trades at the bottom of the page.
Matthew Norwood is Vice President of Sales of the company since July 2016. Prior to joining us, Mr. Norwood served as Area Director of Sales at Merz North America, a medical products company, from November 2014 to July 2016. Prior to Merz, Mr. Norwood held various positions at Ulthera, Inc., a medical device company, from October 2010 to November 2014, including as the Sales Director and South Texas Territory Manager. Prior to Ulthera, Mr. Norwood also held various positions at Ethicon Inc., a subsidiary of Johnson & Johnson that designs medical devices, from February 2005 to October 2010, including as the Market Development Manager and the Senior Full Line Sales Representative. Prior to Ethicon, Mr. Norwood held various positions at Merck & Co., Inc., d.b.a Merck Sharp & Dohme, including as the Osteoporosis Specialty Representative and as a Professional Representative.
Matthew Norwood is 41, he's been the Vice President of Sales of Obalon Therapeutics Inc since 2016. There are 12 older and 1 younger executives at Obalon Therapeutics Inc. The oldest executive at Obalon Therapeutics Inc is Raymond Dittamore, 73, who is the Independent Director.
Matthew's mailing address filed with the SEC is 5421 Avenida Encinas f, Carlsbad, CA 92008, USA.
Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma... y David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.
Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.
Obalon Therapeutics Inc executives and other stock owners filed with the SEC include: